Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 ("POC 2025"). At POC 2025, Microbix will be presenting a poster of results a ...

Core Insights - Microbix Biosystems Inc. reported Q2 and H1 fiscal 2025 results, showing a mixed performance with improved gross margins but a decline in overall revenues compared to the previous year [1][2][6]. Financial Performance - Q2 revenue was $5.3 million, a 5% decrease from $5.6 million in Q2 2024, with antigen revenues increasing by 5% to $4.3 million, while QAPs revenues fell by 38% to $864,320 due to delays in assay-development programs [3][10]. - H1 revenue totaled $11.4 million, a 19% decrease from $14.0 million in H1 2024, influenced by the absence of $4.1 million in Kinlytic licensing payments; excluding this, revenues increased by 14% [6][8]. - Gross margin for Q2 improved to 60% from 53% in the previous year, driven by better manufacturing efficiencies and pricing strategies [4][10]. - H1 gross margin was 61%, slightly down from 65% in H1 2024, but improved by 10% when excluding the impact of Kinlytic licensing revenues [7]. Operating Expenses and Income - Operating expenses in Q2 increased by 21% compared to Q2 2024, primarily due to higher investments in R&D and sales and marketing [4][10]. - Q2 net income was $20,664, a significant drop from $377,730 in Q2 2024, while H1 net income was $877,627 compared to $2.8 million in H1 2024, largely due to the absence of Kinlytic licensing fees [5][8]. Cash Position and Liquidity - Cash and equivalents at the end of Q2 stood at $14.5 million, an increase of $1.5 million from the previous quarter, despite debt repayments and share repurchases [5][10]. - The current ratio improved to 9.68, and the debt to equity ratio decreased to 0.27, indicating enhanced financial strength [9][10]. Business Outlook - Management expressed a cautious outlook for the second half of fiscal 2025, particularly for the Antigens business, due to reduced sales into China [2][11].

Results Release and Webinar Discussion on Morning of May 15, 2025MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix ...

Sequel Pharma Executes Agreement with CDMO for Drug Product ManufacturingMISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Dru ...

Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and aims for revenues of C$ 2.0 million or more per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4][5] Product and Service Offerings - Microbix's antigens support antibody tests for approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The company also develops proprietary products such as Kinlytic, a biologic thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [5] Conference Participation - Microbix will attend and present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5 & 6, 2025 [1][2] - CEO Cameron Groome will present to investors on May 6 at 2:30 p.m. Eastern Time, and senior management will engage in one-on-one meetings with investors [2] Industry Context - The Bloom Burton & Co. Conference aims to connect investors with developments in the Canadian healthcare and life sciences sector [2][3] - Bloom Burton & Co. provides capital raising, M&A advisory, equity research, and strategic advisory services to accelerate returns in the healthcare sector [3]